Clinical Change

Category: Walter and Eliza Hall Institute

Two-pronged attack increases potency of new anti-cancer drugs

The combination of birinapant and p38 inhibitors showed promise in preclinical studies as a new treatment for acute myeloid leukaemia (AML). Both drugs have been studied alone in clinical trials for treating cancer, offering hope that the combination could be safely given to people with AML who have few other treatment options. Dr Najoua Lalaoui, […]

Read More